{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["bempegaldesleukin","nivolumab"],["bempegaldesleukin","nivolumab","ipilimumab"]],"indication":"locally advanced or metastatic solid tumors","name":"PIVOT-02","nct_id":"NCT02983045","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pivot-02-nct02983045. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PIVOT-02","arms":[{"description":"NKTR 214 + nivolumab at 5 dosage levels to determine the RP2D Part 1 of RP2D in patients with advanced or metastatic melanoma, RCC, NSCLC, urothelial carcinoma, or TNBC.","label":"Dose Escalation: Combination of NKTR-214 + nivolumab","type":"EXPERIMENTAL"},{"description":"NKTR-214+nivolumab in patients with advanced or metastatic solid tumor malignancies to assess the efficacy of the RP2D.","label":"Dose Expansion: Combination of NKTR-214 + nivolumab","type":"EXPERIMENTAL"},{"description":"To assess the safety and tolerability of NKTR 214 + nivolumab + ipilimumab triplet therapy and establish RP2D dosing schedules for Part 4 in patients with advanced or metastatic melanoma, RCC, NSCLC, or UCC in a first-line setting (1L).","label":"Experimental: Combination of NKTR-214 + nivolumab + ipilimumab","type":"EXPERIMENTAL"},{"description":"To further assess the RP2D triplet combination dosing schedules from Part 3 in 1L NSCLC and 1L RCC patients.","label":"Experimental: Dose Expansion of Part 3","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2022-04-28","type":"ACTUAL"},"conditions":["Melanoma","Renal Cell Carcinoma","Non Small Cell Lung Cancer","Urothelial Carcinoma","Triple Negative Breast Cancer","HR+/HER2- Breast Cancer","Gastric Cancer"],"enrollment":{"count":557,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Dose Escalation Doublet: Combination of NKTR-214 + nivolumab","otherNames":["Bempegaldesleukin + Opdivo®"],"type":"DRUG"},{"name":"Dose Expansion Doublet: Combination of NKTR-214 + nivolumab","otherNames":["Bempegaldesleukin+ Opdivo®","Carboplatin (Paraplatin®)","Cisplatin (Platinol®)","Pemetrexed (Alimta®)","Paclitaxel (Taxol®)"],"type":"DRUG"},{"name":"Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab","otherNames":["Bempegaldesleukin+ Opdivo®+ Yervoy®"],"type":"DRUG"},{"name":"Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab","otherNames":["Bempegaldesleukin+ Opdivo®+ Yervoy®"],"type":"DRUG"}],"last_update":"2023-03-13","lead_sponsor":"Nektar Therapeutics","official_title":"A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2022-04-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part 1 Dose Escalation: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window","timeFrame":"Includes DLTs that occurred within the DLT window of at least 21 days after the first dose of study treatment (28 days for every 2 weeks dosing; 21 days for every 3 weeks dosing). Patients were counted only once under each preferred term."},{"measure":"Part 3 Schedule Finding: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window","timeFrame":"Dose-limiting toxicities (DLTs) were assessed during a 3-week (21-day) DLT evaluation period beginning with the first dose of ipilimumab."},{"measure":"Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D)","timeFrame":"Tumor assessment at Screening then every 8 weeks (± 7 days) from Cycle 1 Day 1 and end of treatment (unless scan done within 4 weeks) up to approximately 27 months."}],"references":[{"citation":"Bautista J, Echeverria CE, Maldonado-Noboa I, Adatty-Molina J, Suarez Urresta S, Coral-Riofrio EC, Araujo-Abad S, Kyriakidis NC, Lopez-Cortes A. Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy. J Immunol Res. 2026;2026(1):e7864229. doi: 10.1155/jimr/7864229.","pmid":"41811823","type":"DERIVED"},{"citation":"Siefker-Radtke AO, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Hurwitz ME, Tannir NM. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. Eur Urol. 2022 Oct;82(4):365-373. doi: 10.1016/j.eururo.2022.05.002. Epub 2022 May 25.","pmid":"35643589","type":"DERIVED"},{"citation":"Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, Jang S, Kalinka E, Puzanov I, Spira AI, Cho DC, Guan S, Puente E, Nguyen T, Hoch U, Currie SL, Lin W, Tagliaferri MA, Zalevsky J, Sznol M, Hurwitz ME. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. J Clin Oncol. 2021 Sep 10;39(26):2914-2925. doi: 10.1200/JCO.21.00675. Epub 2021 Jul 13.","pmid":"34255535","type":"DERIVED"},{"citation":"Veatch JR, Singhi N, Jesernig B, Paulson KG, Zalevsky J, Iaccucci E, Tykodi SS, Riddell SR. Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab. J Immunother Cancer. 2020 Dec;8(2):e001591. doi: 10.1136/jitc-2020-001591.","pmid":"33298619","type":"DERIVED"}],"start_date":{"date":"2016-12-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT02983045"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pivot-02-nct02983045"}